History & Innovation
10 min read
Last reviewed: October 2026 · Next review due: October 2027
The Evolution of Rhesus Typing Technology
Rhesus typing has changed substantially since 1940, from manual slide tests to molecular analysis. Each step has made transfusion safer and improved the management of Rh-related complications. This article traces the main developments across eight decades.
85 Years of Innovation
- 1940: Discovery of the Rhesus factor
- 1960s: Development of anti-D immunoglobulin prophylaxis
- 1980s: Monoclonal antibodies standardise typing reagents
- 1990s: Molecular methods emerge
- 2020s: AI and automation transform blood banking
The Five Eras of Rhesus Typing
Discovery Era
1940-1950
Initial identification of Rh factor, basic slide tests, understanding of HDFN
Development Era
1950-1970
Tube testing, Coombs test, exchange transfusion for HDFN established, anti-D immunoglobulin prophylaxis developed
Automation Era
1970-1990
Column agglutination technology, microplates, automated readers, standardisation
Molecular Era
1990-2010
Gene discovery, PCR methods, microarrays, genotyping
Integration Era
2010-Present
NGS, AI interpretation, point-of-care testing, personalised medicine
Key Milestones in Rhesus Technology
1940
Discovery of the Rh Factor
Karl Landsteiner and Alexander Wiener discover the Rhesus factor using rhesus monkey red cells. This breakthrough explains previously mysterious transfusion reactions and newborn deaths.
1945
Coombs Test Development
Coombs, Mourant, and Race describe the antiglobulin test, enabling detection of incomplete antibodies and weak D antigens. This remains a cornerstone technique today.
1963
First Intrauterine Transfusion
A. William Liley performs the first successful intrauterine transfusion for severe HDFN in New Zealand, making it possible to treat severely affected fetuses before birth. Exchange transfusion for HDFN had already been established as standard postnatal treatment since the late 1940s (Wallerstein 1946; Diamond et al. 1948).
1968
Anti-D Immunoglobulin Introduced
Anti-D immunoglobulin (marketed in the US as RhoGAM) is licensed for prevention of D sensitisation, reducing the incidence of Rh D HDFN by over 95% where it is used routinely.
1982
Monoclonal Antibodies
Development of monoclonal anti-D reagents provides consistent, unlimited supply of typing reagents with standardised specificity.
1990
Gel Card Technology
Lapierre et al. publish column agglutination technology (CAT/gel card testing), which gives blood typing more standardised, stable, and easily read results.
1990–1992
Rh Genes Cloned
RHCE cDNA is cloned in 1990 and RHD in 1992, opening the door to molecular blood group typing and to understanding the genetic basis of variants.
Late 90s to early 2000s
Fetal RHD Testing
Non-invasive prenatal RHD testing from maternal plasma becomes possible, allowing targeted anti-D immunoglobulin prophylaxis.
2010
High-Throughput Genotyping
Microarray platforms enable testing of multiple blood group systems simultaneously, improving donor-recipient matching.
2020
AI Integration
Artificial intelligence begins interpreting complex serological patterns and predicting rare phenotypes from genetic data.
Evolution of Testing Methods
From Manual to Automated
Typing moved from slide agglutination in the 1940s to tube testing, then microplates in the 1980s, column agglutination in the 1990s and fully automated platforms from the 2000s. Each step made results more standardised and less dependent on the person reading them.
Technology Comparison Across Eras
1940s
Manual observation
Subjective reading
1970s
Standardised reagents
Quality control
2000s
Full automation
Electronic records
2020s
Molecular integration
AI assistance
Anti-D Prophylaxis: A Turning Point
The introduction of anti-D immunoglobulin in the 1960s sharply reduced HDFN caused by anti-D:
- Before prophylaxis: roughly 13–16% of D-negative women carrying a D-positive fetus became sensitised
- After prophylaxis: reduced to well under 1% with routine antenatal and postnatal prophylaxis
- Effect: far fewer pregnancies are affected, although anti-D remains the most common cause of HDFN
Modern Innovations
Current State-of-the-Art
2020s Technology
- Next-Generation Sequencing: Complete RH gene analysis
- Digital PCR: Precise quantification of fetal DNA in maternal blood
- Mass Spectrometry: Protein-level antigen detection
- Microfluidics: Point-of-care testing with minimal sample
- Machine Learning: Pattern recognition and outcome prediction
Emerging Technologies
Several developments could shape Rhesus typing over the next decade:
Future Innovations
- Point-of-care genotyping: Rapid molecular typing closer to the bedside
- Nanopore sequencing: Faster, portable genotyping
- Expanded cell-free fetal DNA testing: Non-invasive fetal typing beyond RHD
- Cultured red cells: Lab-grown units with defined antigen profiles
Global Impact and Access
Technology Distribution
Access to newer technology varies widely between countries:
- Developed countries: Molecular typing, automated systems
- Middle-income: Column agglutination technology, semi-automated platforms
- Resource-limited: Basic slide and tube methods
- Challenge: Making advanced technology accessible globally
Looking Forward
The evolution of Rhesus typing technology continues to accelerate. Future developments promise:
- Instant bedside genotyping for emergency situations
- AI-driven personalised transfusion strategies
- Universal donor blood through genetic modification
- Preventive therapies beyond anti-D immunoglobulin
- Global real-time blood matching networks
Key Takeaways
- Rhesus typing has progressed from simple slide tests to molecular analysis
- Each technological advance has improved accuracy and saved lives
- The development of anti-D immunoglobulin remains one of medicine's greatest preventive successes
- Automation and standardisation have made testing safer and more reliable
- Molecular methods now complement traditional serology
- Future innovations promise personalised, precise blood matching
- Global access to advanced technology remains a challenge
Rhesus typing has progressed from Landsteiner's first observations to automated and molecular platforms, and each advance has made transfusion safer. Work continues on faster genotyping, non-invasive fetal testing, and cultured red cells, with the same aim throughout: reliable matching and fewer Rh-related complications.
↑ Back to Top
References
- Landsteiner K, Wiener AS. An agglutinable factor in human blood recognised by immune sera for rhesus blood. Proc Soc Exp Biol Med. 1940;43:223–224.
- Coombs RRA, Mourant AE, Race RR. A new test for the detection of weak and “incomplete” Rh agglutinins. Br J Exp Pathol. 1945;26(4):255–266.
- Liley AW. Intrauterine transfusion of foetus in haemolytic disease. Br Med J. 1963;2(5365):1107–1109.
- Lapierre Y, Rigal D, Adam J, et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion. 1990;30(2):109–113.
- Cherif-Zahar B, Bloy C, Le Van Kim C, et al. Molecular cloning and protein structure of a human blood group Rh polypeptide. Proc Natl Acad Sci U S A. 1990;87(16):6243–6247.
- Le Van Kim C, Mouro I, Chérif-Zahar B, et al. Molecular cloning and primary structure of the human blood group RhD polypeptide. Proc Natl Acad Sci U S A. 1992;89(22):10925–10929.
- Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–487.
- Daniels G. Human Blood Groups. 3rd ed. Oxford: Wiley-Blackwell; 2013.